[go: up one dir, main page]

SE9900495D0 - Vaccine composition - Google Patents

Vaccine composition

Info

Publication number
SE9900495D0
SE9900495D0 SE9900495A SE9900495A SE9900495D0 SE 9900495 D0 SE9900495 D0 SE 9900495D0 SE 9900495 A SE9900495 A SE 9900495A SE 9900495 A SE9900495 A SE 9900495A SE 9900495 D0 SE9900495 D0 SE 9900495D0
Authority
SE
Sweden
Prior art keywords
sub
vaccine composition
monoglyceride
killed
tuberculosis
Prior art date
Application number
SE9900495A
Other languages
English (en)
Swedish (sv)
Inventor
Ulf Scroeder
Stefan Svenson
Original Assignee
Pharmatrix Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmatrix Ab filed Critical Pharmatrix Ab
Priority to SE9900495A priority Critical patent/SE9900495D0/xx
Publication of SE9900495D0 publication Critical patent/SE9900495D0/xx
Priority to AU28035/00A priority patent/AU769390B2/en
Priority to ES00906305T priority patent/ES2275495T3/es
Priority to AT00906305T priority patent/ATE342065T1/de
Priority to PCT/EP2000/001046 priority patent/WO2000047225A2/fr
Priority to DK00906305T priority patent/DK1154792T3/da
Priority to US09/926,001 priority patent/US6936260B1/en
Priority to NZ513130A priority patent/NZ513130A/xx
Priority to DE60031243T priority patent/DE60031243T2/de
Priority to EP00906305A priority patent/EP1154792B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9900495A 1999-02-12 1999-02-12 Vaccine composition SE9900495D0 (sv)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE9900495A SE9900495D0 (sv) 1999-02-12 1999-02-12 Vaccine composition
AU28035/00A AU769390B2 (en) 1999-02-12 2000-02-09 Vaccine composition
ES00906305T ES2275495T3 (es) 1999-02-12 2000-02-09 Formulacion de la vacuna contra la tuberculosis que contiene como adyuvante monogliceridos o acidos grasos.
AT00906305T ATE342065T1 (de) 1999-02-12 2000-02-09 Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
PCT/EP2000/001046 WO2000047225A2 (fr) 1999-02-12 2000-02-09 Composition de vaccin
DK00906305T DK1154792T3 (da) 1999-02-12 2000-02-09 Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans
US09/926,001 US6936260B1 (en) 1999-02-12 2000-02-09 Vaccine composition
NZ513130A NZ513130A (en) 1999-02-12 2000-02-09 Vaccine composition containing a monoglyceride adjuvant with inactivated Mycobacterium tuberculosis bacteria
DE60031243T DE60031243T2 (de) 1999-02-12 2000-02-09 Impfstofformulierung gegen tuberkulose mit monoglyceriden oder fettsäuren als adjuvant
EP00906305A EP1154792B1 (fr) 1999-02-12 2000-02-09 Composition de vaccin contre la tuberculose contenant des monoglycerides d'acides gras comme adjuvant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900495A SE9900495D0 (sv) 1999-02-12 1999-02-12 Vaccine composition

Publications (1)

Publication Number Publication Date
SE9900495D0 true SE9900495D0 (sv) 1999-02-12

Family

ID=20414469

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9900495A SE9900495D0 (sv) 1999-02-12 1999-02-12 Vaccine composition

Country Status (10)

Country Link
US (1) US6936260B1 (fr)
EP (1) EP1154792B1 (fr)
AT (1) ATE342065T1 (fr)
AU (1) AU769390B2 (fr)
DE (1) DE60031243T2 (fr)
DK (1) DK1154792T3 (fr)
ES (1) ES2275495T3 (fr)
NZ (1) NZ513130A (fr)
SE (1) SE9900495D0 (fr)
WO (1) WO2000047225A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR030800A0 (en) * 2000-09-22 2000-10-12 Pharmalink International Limited Immunomodulatory preparation
KR20040081423A (ko) * 2001-11-14 2004-09-21 노바백스, 인코포레이티드 마이코박테륨 백신
JP4737586B2 (ja) * 2001-12-11 2011-08-03 インスティティ・パスツール 免疫調節不全を含む疾患の治療のためのグラム陽性細菌調製物
CU23476A1 (es) * 2004-01-29 2009-12-17 Ct Ingenieria Genetica Biotech Formulación adyuvante conteniendo una emulsión oleosa con aceite de jojoba
EP1843787B1 (fr) * 2005-01-28 2011-11-02 North-West University Combinaison de lipides et d'oxyde nitreux comme adjuvant pour renforcer l'efficacité de vaccins
HUE024427T2 (en) * 2007-04-12 2016-01-28 Mico Bio Inc Use of tuberculosis vaccine and procedure
CN102441162B (zh) * 2010-10-04 2018-07-24 免疫产品美国股份有限公司 结核病的治疗和预防
MX2013012165A (es) * 2011-04-20 2014-06-11 Mico Bio Inc Composicion y metodo para mejorar una respuesta inmune.
EP2620159A1 (fr) * 2012-01-24 2013-07-31 Institut Pasteur Traitement du cancer amélioré par immunothérapie par BCG ou des mycobactéries non pathogènes apparentées du point de vue des antigènes
WO2018006939A1 (fr) 2016-07-05 2018-01-11 Universidad De Zaragoza Vaccin inactivé contre la tuberculose.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014837A1 (fr) * 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
WO1993006921A1 (fr) 1991-10-04 1993-04-15 Gs Biochem Ab Particules, procede de preparation desdites particules et utilisations
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
ATE318147T1 (de) * 1996-03-25 2006-03-15 Medarex Inc Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
SE9602280D0 (sv) 1996-06-10 1996-06-10 Pharmatrix Ab Immunstimulerande lipidformulering

Also Published As

Publication number Publication date
WO2000047225A2 (fr) 2000-08-17
DE60031243D1 (de) 2006-11-23
WO2000047225A3 (fr) 2000-12-14
EP1154792B1 (fr) 2006-10-11
EP1154792A2 (fr) 2001-11-21
DE60031243T2 (de) 2007-05-24
AU769390B2 (en) 2004-01-22
AU2803500A (en) 2000-08-29
NZ513130A (en) 2003-01-31
DK1154792T3 (da) 2007-02-12
US6936260B1 (en) 2005-08-30
ATE342065T1 (de) 2006-11-15
ES2275495T3 (es) 2007-06-16

Similar Documents

Publication Publication Date Title
RU2159761C2 (ru) Замещенные 4-биарилмасляные или 5-биарилпентановые кислоты или их производные, способы их получения, фармацевтическая композиция и способ лечения
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
EP1955709A3 (fr) Compositions d'adjuvant d'amélioration des réponses immunitaires aux vaccins à base de polynucléotide
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
MD1586G2 (ro) Inducere a unui răspuns citotoxic T-limfocitar
DE122010000041I1 (de) Solubilisierung von capsulären Polysacchariden
CY1106206T1 (el) Φαρμακευτικη συνθεση πepιεχουσα φενοφιβρατη και μεθοδος παρασκευης της
NO20002741D0 (no) Vaksine-blandinger omfattende kitosan, for mukosal administrasjon
NZ513202A (en) Antigen composition comprising Bordetella bronchiseptica, formalin and glutaraldehyde
ATE195740T1 (de) Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
ATE233101T1 (de) Polynukleotide vakzine gegen den papilloma virus
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
MXPA04000680A (es) Vacuna para virus west nile.
SE9900495D0 (sv) Vaccine composition
DE60202379D1 (de) Neuartige verbindungen
FI972054A0 (fi) Immunogeenisiä koostumuksia
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
SE9900496D0 (sv) Vaccine formulation
EP2364726A3 (fr) Vaccin contre l'infection Neisseria
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
PL365334A1 (en) Use of zinc derivatives as cyclic ester polymerisation catalysts
SE9402241D0 (sv) Inhibitor
GEP20053444B (en) Immunogenic Liposome Compositions
BR0008949A (pt) Composições de lipoglicano e métodos de tratamento de infecções parasitárias
ATE397615T1 (de) 6-o-alkyl-2-nor-2-substituierte ketolidderivate